Mallinckrodt buying Cadence Pharma for $1.21B

February 11, 2014

Health care products company Mallinckrodt is buying Cadence Pharmaceuticals Inc. for about $1.21 billion to help enhance its specialty pharmaceuticals segment.

San Diego-based Cadence is a that concentrates on commercializing products most for use at hospitals.

Ireland's Mallinckrodt PLC will pay $14 per , a 27 percent premium to Cadence's Monday closing price of $1107. The companies put the 's value at about $1.3 billion.

Cadence has approximately 86.1 million outstanding shares, according to FactSet.

Both companies' boards unanimously approved the transaction.

Cadence will become a Mallinckrodt subsidiary.

Mallinckrodt said Tuesday that it expects the acquisition to immediately add to its fiscal 2014 adjusted earnings per share and significantly add to its fiscal 2015 adjusted earnings per share.

The deal is targeted to close in mid- to late-March.

Explore further: Avago Technologies buying LSI for $6.6B (Update)

Related Stories

IBM posts higher 4Q net income (Update)

January 21, 2014

IBM's fourth-quarter net income grew 6 percent, surpassing Wall Street's expectations even though revenue fell. Its shares fell in extended trading after the results came out—and CEO Ginni Rometty said she's recommending ...

Recommended for you


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.